Propanc Biopharma, Inc.
PPCB · XNASCIK 1517681fmd_0MH729REF209ES2866FTX2VH70Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jul 02, 2007 to Jun 30, 2026, 67 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Research and development | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Total operating expenses | 6 | 4 | 3 | 3 | 2 | 2 | 2 | 2 | 57 | 18 |
| Operating income | (6) | (4) | (3) | (3) | (2) | (2) | (2) | (2) | (57) | (18) |
| Interest expense | 3 | 3 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | (2) | (3) | (3) | (1) | (0) | (1) | (1) | (0) | (2) | (1) |
| Income before taxes | – | (7) | (6) | (5) | (2) | (3) | (3) | (2) | (59) | (19) |
| Income tax expense | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | – | – |
| Net income from continuing operations | – | (7) | (6) | (5) | (2) | (3) | (3) | (2) | – | – |
| Net income | (8) | (7) | (6) | (5) | (2) | (3) | (3) | (2) | (59) | (19) |
| Net income to common shareholders | – | – | – | (5) | (2) | (3) | (3) | (2) | (59) | (20) |